{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:50:45Z","timestamp":1788310245206,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,5,12]],"date-time":"2012-05-12T00:00:00Z","timestamp":1336780800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1007\/s11904-012-0120-1","type":"journal-article","created":{"date-parts":[[2012,5,11]],"date-time":"2012-05-11T11:53:18Z","timestamp":1336737198000},"page":"259-266","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of Latent Tuberculosis Infection in HIV: Shorter or Longer?"],"prefix":"10.1007","volume":"9","author":[{"given":"Anna K.","family":"Person","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Sterling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,5,12]]},"reference":[{"issue":"9","key":"120_CR1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJM198903023200901","volume":"320","author":"PA Selwyn","year":"1989","unstructured":"\u2022 Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989;320(9):545\u201350. Often-cited paper on the high annual risk of progression to active tuberculosis among HIV-infected persons with M. tuberculosis infection who do not receive treatment for either infection.","journal-title":"N Engl J Med"},{"issue":"1","key":"120_CR2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/00042560-200001010-00010","volume":"23","author":"R Wood","year":"2000","unstructured":"Wood R, Maartens G, Lombard CJ. Risk factors for developing tuberculosis in HIV-1-infected adults from communities with a low or very high incidence of tuberculosis. J Acquir Immune Defic Syndr. 2000;23(1):75\u201380.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"120_CR3","unstructured":"Global Tuberculosis Control 2011; Geneva, Switzerland. WHO Report 2011. 2011 Nov. 7; 1\u2013258. Available from: http:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"key":"120_CR4","first-page":"CD000171","volume":"1","author":"C Akolo","year":"2010","unstructured":"Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171.","journal-title":"Cochrane Database Syst Rev"},{"key":"120_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/1471-2334-10-267","volume":"10","author":"A Diaz","year":"2010","unstructured":"Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, et al. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis. 2010;10:267.","journal-title":"BMC Infect Dis"},{"issue":"2","key":"120_CR6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1378\/chest.09-0394","volume":"137","author":"CR Horsburgh","year":"2010","unstructured":"Horsburgh CR, Goldberg S, Bethel J, Chen S, Colson PW, Hirsch-Moverman Y, et al. Latent TB infection treatment acceptance and completion in the United States and Canada. Chest. 2010;137(2):401\u20139.","journal-title":"Chest"},{"key":"120_CR7","unstructured":"Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living with HIV in resource constrained settings. Geneva, Switzerland. WHO 2011."},{"issue":"4","key":"120_CR8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","volume":"170","author":"D Menzies","year":"2004","unstructured":"Menzies D, Dion M-J, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. Treatment completion and costs of a randomized trial of rifampin for 4\u00a0months versus isoniazid for 9\u00a0months. Am J Respir Crit Care Med. 2004;170(4):445\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"120_CR9","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1378\/chest.130.6.1712","volume":"130","author":"A Lardizabal","year":"2006","unstructured":"Lardizabal A, Passannante M, Kojakali F, Hayden C, Reichman LB. Enhancement of treatment completion for latent tuberculosis infection with 4\u00a0months of rifampin. Chest. 2006;130(6):1712\u20137.","journal-title":"Chest"},{"issue":"17","key":"120_CR10","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/archinte.166.17.1863","volume":"166","author":"KR Page","year":"2006","unstructured":"Page KR, Sifakis F, Montes de Oca R, Cronin WA, Doherty MC, Federline L, et al. Improved adherence and less toxicity with rifampin vs isoniazid for treatment of latent tuberculosis: a retrospective study. Arch Intern Med. 2006;166(17):1863\u201370.","journal-title":"Arch Intern Med"},{"issue":"1","key":"120_CR11","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1011214","volume":"365","author":"SA Madhi","year":"2011","unstructured":"Madhi SA, Nachman S, Violari A, Kim S, Cotton MF, Bobat R, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med. 2011;365(1):21\u201331.","journal-title":"N Engl J Med"},{"issue":"2","key":"120_CR12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00002030-200101260-00011","volume":"15","author":"MA Quigley","year":"2001","unstructured":"Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JDH, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS. 2001;15(2):215\u201322.","journal-title":"AIDS"},{"issue":"16","key":"120_CR13","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1097\/00002030-200111090-00009","volume":"15","author":"JL Johnson","year":"2001","unstructured":"Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluuza Kityo C, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS. 2001;15(16):2137\u201347.","journal-title":"AIDS"},{"issue":"9777","key":"120_CR14","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","volume":"377","author":"T Samandari","year":"2011","unstructured":"\u2022\u2022 Samandari T, Agizew TB, Nyirenda S, Tedla Z, Sibanda T, Shang N, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9777):1588\u201398. A study of the effect of prolonged isoniazid treatment among HIV-infected persons in a high tuberculosis incidence area (Botswana), where the risk of M. tuberculosis re-infection is high. Also assessed tuberculosis risk according to tuberculin skin test status and receipt of antiretroviral therapy.","journal-title":"Lancet"},{"issue":"1","key":"120_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1005136","volume":"365","author":"NA Martinson","year":"2011","unstructured":"\u2022\u2022 Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med. 2011;365(1):11\u201320. Conducted among HIV-infected persons in South Africa, this study demonstrated no significant difference in the protective effect of four regimens: 3\u00a0months of once-weekly isoniazid\u2009+\u2009rifapentine (directly-observed), 3\u00a0months of twice-weekly isoniazid\u2009+\u2009rifampin (directly-observed), 6\u00a0months of daily isoniazid (self-administered), and up to 6\u00a0years of daily isoniazid (self-administered). The continuous isoniazid regimen was poorly tolerated.","journal-title":"N Engl J Med"},{"issue":"23","key":"120_CR16","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","volume":"365","author":"TR Sterling","year":"2011","unstructured":"\u2022\u2022 Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155\u201366. Although most of the study population was HIV-uninfected, this study conducted in low and medium tuberculosis incidence countries demonstrated that 3\u00a0months of once-weekly isoniazid\u2009+\u2009rifapentine (directly-observed) was at least as effective as 9\u00a0months of daily isoniazid (self-administered). The tolerability of both regimens was similar.","journal-title":"N Engl J Med"},{"issue":"9323","key":"120_CR17","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(02)08904-3","volume":"359","author":"M Badri","year":"2002","unstructured":"Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059\u201364.","journal-title":"Lancet"},{"issue":"4","key":"120_CR18","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1086\/338641","volume":"34","author":"G Santoro-Lopes","year":"2002","unstructured":"Santoro-Lopes G, de Pinho AMF, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis. 2002;34(4):543\u20136.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"120_CR19","first-page":"1026","volume":"4","author":"JL Jones","year":"2000","unstructured":"Jones JL, Hanson DL, Dworkin MS, DeCock KM, Adult\/Adolescent Spectrum of HIV Disease Group. HIV-associated tuberculosis in the era of highly active antiretroviral therapy. The Adult\/Adolescent Spectrum of HIV Disease Group. Int J Tuberc Lung Dis. 2000;4(11):1026\u201331.","journal-title":"Int J Tuberc Lung Dis"},{"issue":"7","key":"120_CR20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1473-3099(10)70078-5","volume":"10","author":"SD Lawn","year":"2010","unstructured":"Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010;10(7):489\u201398.","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"120_CR21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5588\/ijtld.10.0483","volume":"15","author":"SD Lawn","year":"2011","unstructured":"Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis. 2011;15(5):571\u201381.","journal-title":"Int J Tuberc Lung Dis"},{"key":"120_CR22","unstructured":"www.clinicaltrials.gov [Internet]. [cited 2012 Mar. 29]. Available from: http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00463086?term=Isoniazid+Plus+%28Highly+Active+Antiretroviral+Therapy%29+HAART+to+Prevent+Tuberculosis+%28TB%29+in+HIV-infected+Persons+%28HAART-IPT%29&rank=1"},{"key":"120_CR23","unstructured":"www.clinicaltrials.gov [Internet]. [cited 2012 Mar. 29]. Available from: http:\/\/clinicaltrials.gov\/ct2\/results?term=Early+Antiretroviral+Treatment+and%2For+Early+Isoniazid+Prophylaxis+Against+Tuberculosis+in+HIV-infected+Adults+"},{"issue":"11","key":"120_CR24","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1097\/QAD.0b013e328216f441","volume":"21","author":"JE Golub","year":"2007","unstructured":"Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS. 2007;21(11):1441\u20138.","journal-title":"AIDS"},{"issue":"5","key":"120_CR25","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/QAD.0b013e328327964f","volume":"23","author":"JE Golub","year":"2009","unstructured":"Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631\u20136.","journal-title":"AIDS"},{"issue":"5","key":"120_CR26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1056\/NEJM199707313370505","volume":"337","author":"FM Gordin","year":"1997","unstructured":"\u2022 Gordin FM, Matts JP, Miller C, Brown LS, Hafner R, John SL, et al. A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1997;337(5):315\u201320. As has been subsequently demonstrated in other studies, there was no significant decrease in tuberculosis risk among anergic HIV-infected persons who received isoniazid preventive therapy.","journal-title":"N Engl J Med"},{"issue":"9777","key":"120_CR27","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1016\/S0140-6736(11)60434-0","volume":"377","author":"LE Dodd","year":"2011","unstructured":"Dodd LE, Wilkinson RJ. Isoniazid preventive therapy in HIV infection. Lancet. 2011;377(9777):1548\u201350.","journal-title":"Lancet"},{"issue":"5","key":"120_CR28","first-page":"827","volume":"119","author":"GW Comstock","year":"1979","unstructured":"Comstock GW, Baum C, Snider DE. Isoniazid prophylaxis among Alaskan Eskimos: a final report of the bethel isoniazid studies. Am Rev Respir Dis. 1979;119(5):827\u201330.","journal-title":"Am Rev Respir Dis"},{"issue":"18","key":"120_CR29","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1097\/00002030-199818000-00014","volume":"12","author":"A Mwinga","year":"1998","unstructured":"Mwinga A, Hosp M, Godfrey-Faussett P, Quigley M, Mwaba P, Mugala BN, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS. 1998;12(18):2447\u201357.","journal-title":"AIDS"},{"key":"120_CR30","unstructured":"sterlit. Supplementary Appendix. New England Journal of Medicine [Internet]. 2011 Dec. 8;365(23):1\u201323. Available from: http:\/\/nejm.org"},{"issue":"7","key":"120_CR31","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/QAD.0b013e32833849df","volume":"24","author":"CL Halsema van","year":"2010","unstructured":"van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJC, Churchyard GJ, et al. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24(7):1051\u20135.","journal-title":"AIDS"},{"issue":"5","key":"120_CR32","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","volume":"12","author":"ME Balcells","year":"2006","unstructured":"Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744\u201351.","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"120_CR33","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1086\/429825","volume":"40","author":"L Mtei","year":"2005","unstructured":"Mtei L, Matee M, Herfort O, Bakari M, Horsburgh CR, Waddell R, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis. 2005;40(10):1500\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9167","key":"120_CR34","first-page":"1843","volume":"353","author":"A Vernon","year":"1999","unstructured":"Vernon A, Burman W, Benator D, Khan A, Bozeman L. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberc Trials Consortium Lancet. 1999;353(9167):1843\u20137.","journal-title":"Tuberc Trials Consortium Lancet"},{"issue":"11","key":"120_CR35","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1164\/rccm.200311-1612OC","volume":"169","author":"M Weiner","year":"2004","unstructured":"Weiner M, Bock N, Peloquin CA, Burman WJ, Khan A, Vernon A, et al. Pharmacokinetics of rifapentine at 600, 900, and 1,200\u00a0mg during once-weekly tuberculosis therapy. Am J Respir Crit Care Med. 2004;169(11):1191\u20137.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"120_CR36","doi-asserted-by":"crossref","first-page":"e1000391","DOI":"10.1371\/journal.pmed.1000391","volume":"8","author":"H Getahun","year":"2011","unstructured":"Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med. 2011;8(1):e1000391.","journal-title":"PLoS Med"},{"key":"120_CR37","first-page":"1650","volume":"60","author":"Centers for Disease Control and Prevention CDC","year":"2011","unstructured":"Centers for Disease Control and Prevention CDC. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011;60:1650\u20133.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"120_CR38","unstructured":"Short-Course (3-Month) Therapy with Weekly Isoniazid-Rifapentine Is NOT RECOMMENDED for HIV-Infected Patients Receiving Antiretroviral Therapy (December20, 2011). http:\/\/aidsinfo.nih.gov\/Guidelines\/Default.aspx . Accessed March 26, 2012."},{"issue":"12","key":"120_CR39","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1086\/647944","volume":"49","author":"PD Ziakas","year":"2009","unstructured":"Ziakas PD, Mylonakis E. 4\u00a0months of rifampin compared with 9\u00a0months of isoniazid for the management of latent tuberculosis infection: a meta-analysis and cost-effectiveness study that focuses on compliance and liver toxicity. Clin Infect Dis. 2009;49(12):1883\u20139.","journal-title":"Clin Infect Dis"},{"issue":"11","key":"120_CR40","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1164\/rccm.200901-0153OC","volume":"179","author":"DP Holland","year":"2009","unstructured":"Holland DP, Sanders GD, Hamilton CD, Stout JE. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection. Am J Respir Crit Care Med. 2009;179(11):1055\u201360.","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0120-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11904-012-0120-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-012-0120-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T20:15:46Z","timestamp":1559420146000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-012-0120-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["120"],"URL":"https:\/\/doi.org\/10.1007\/s11904-012-0120-1","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,12]]}}}